SMYD3 and hepatocellular carcinoma: Furthermore, patients with HCC overexpressing SMYD3 had more aggressive microvascular invasion (ratio: 43/94 vs. 15/54, p = 0.031) and a more advanced pTNM stage (ratio: 52/94 vs. 19/35, p = 0.018) than patients with low levels of SMYD3 (Fig. 1D).